AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of 240.81 billion. The enterprise value is 266.48 billion.
| Market Cap | 240.81B |
| Enterprise Value | 266.48B |
Important Dates
The last earnings date was Tuesday, July 29, 2025.
| Earnings Date | Jul 29, 2025 |
| Ex-Dividend Date | Aug 7, 2025 |
Share Statistics
| Current Share Class | 1.55B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.06% |
| Shares Change (QoQ) | -0.13% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 29.03 and the forward PE ratio is 15.88.
| PE Ratio | 29.03 |
| Forward PE | 15.88 |
| PS Ratio | 4.26 |
| PB Ratio | 5.37 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 21.55 |
| P/OCF Ratio | 17.99 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.84, with an EV/FCF ratio of 23.84.
| EV / Earnings | 32.13 |
| EV / Sales | 4.76 |
| EV / EBITDA | 13.84 |
| EV / EBIT | 18.78 |
| EV / FCF | 23.84 |
Financial Position
The company has a current ratio of 0.86, with a Debt / Equity ratio of 0.74.
| Current Ratio | 0.86 |
| Quick Ratio | 0.66 |
| Debt / Equity | 0.74 |
| Debt / EBITDA | 1.69 |
| Debt / FCF | 2.95 |
| Interest Coverage | 10.77 |
Financial Efficiency
Return on equity (ROE) is 19.67% and return on invested capital (ROIC) is 11.88%.
| Return on Equity (ROE) | 19.67% |
| Return on Assets (ROA) | 8.28% |
| Return on Invested Capital (ROIC) | 11.88% |
| Return on Capital Employed (ROCE) | 18.19% |
| Revenue Per Employee | 599,162 |
| Profits Per Employee | 87,964 |
| Employee Count | 94,300 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 1.65 |
Taxes
In the past 12 months, AstraZeneca has paid 1.72 billion in taxes.
| Income Tax | 1.72B |
| Effective Tax Rate | 17.17% |
Stock Price Statistics
The stock price has decreased by -3.99% in the last 52 weeks. The beta is 0.15, so AstraZeneca's price volatility has been lower than the market average.
| Beta (5Y) | 0.15 |
| 52-Week Price Change | -3.99% |
| 50-Day Moving Average | 144.57 |
| 200-Day Moving Average | 140.56 |
| Relative Strength Index (RSI) | 60.41 |
| Average Volume (20 Days) | 3,278 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AstraZeneca had revenue of 56.50 billion and earned 8.30 billion in profits. Earnings per share was 5.31.
| Revenue | 56.50B |
| Gross Profit | 46.48B |
| Operating Income | 14.35B |
| Pretax Income | 10.02B |
| Net Income | 8.30B |
| EBITDA | 19.13B |
| EBIT | 14.35B |
| Earnings Per Share (EPS) | 5.31 |
Balance Sheet
The company has 7.11 billion in cash and 32.94 billion in debt, giving a net cash position of -25.83 billion.
| Cash & Cash Equivalents | 7.11B |
| Total Debt | 32.94B |
| Net Cash | -25.83B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 44.81B |
| Book Value Per Share | 28.85 |
| Working Capital | -4.60B |
Cash Flow
In the last 12 months, operating cash flow was 13.39 billion and capital expenditures -2.21 billion, giving a free cash flow of 11.18 billion.
| Operating Cash Flow | 13.39B |
| Capital Expenditures | -2.21B |
| Free Cash Flow | 11.18B |
| FCF Per Share | n/a |
Margins
Gross margin is 82.26%, with operating and profit margins of 25.40% and 14.68%.
| Gross Margin | 82.26% |
| Operating Margin | 25.40% |
| Pretax Margin | 17.74% |
| Profit Margin | 14.68% |
| EBITDA Margin | 33.85% |
| EBIT Margin | 25.40% |
| FCF Margin | 19.78% |
Dividends & Yields
This stock pays an annual dividend of 3.13, which amounts to a dividend yield of 2.03%.
| Dividend Per Share | 3.13 |
| Dividend Yield | 2.03% |
| Dividend Growth (YoY) | 213.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 59.51% |
| Buyback Yield | -0.06% |
| Shareholder Yield | 1.97% |
| Earnings Yield | 3.44% |
| FCF Yield | 4.64% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AstraZeneca has an Altman Z-Score of 2.98 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.98 |
| Piotroski F-Score | 6 |